Literatur
-
1
Möller H J.
Therapieresistenz auf Antidepressiva.
Nervenarzt.
2004;
75
499-517
-
2
Möller H J.
Medikamentöse Therapiestrategien bei therapieresistenter unipolarer Depression.
Psychopharmakotherapie.
2004;
11
34-41
-
3
Souery D, Papakostas G I, Trivedi M H.
Treatment-resistant depression.
J Clin Psychiatry.
2006;
67 (Suppl 6)
16-22
-
4
Adli M, Baethge C, Heinz A. et al .
Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review.
Eur Arch Psychiatry Clin Neurosci.
2005;
255
387-400
-
5
Harrison C L, Ferrier N, Young A H.
Tolerability of high-dose venlafaxine in depressed patients.
J Psychopharmacol.
2004;
18
200-204
-
6
Thase M E, Shelton R C, Khan A.
Treatment with venlafaxine extended release after SSRI nonresponse or intolerance: a randomized comparison of standard- and higher-dosing strategies.
J Clin Psychopharmacol.
2006;
26
250-258
-
7
Thase M E, Rush A J.
When at first you don’t succeed: sequential strategies for antidepressant nonresponsers.
J Clin Psychiatry.
1997;
58 (Suppl 1)
23-29
-
8
Thase M E, Feighner J P, Lydiard R B.
Citalopram treatment of fluoxetine nonresponders.
J Clin Psychiatry.
2001;
62
683-687
-
9
Fava M, McGrath P J, Sheu W P. et al .
Switching fluoxetine to reboxetine: an efficacy and safety study in depressed patients resistant to fluoxetine (abstract p03.198).
Int J Neuropsychopharmacol.
2000;
3
234
-
10 Thase M E, Rush A J. Treatment-resistant depression. Bloom FE, Kupfer DJ Psychopharmacology: the fourth generation of progress New York; Raven Press 1995: 1081-1097
-
11 AHCPR .Depression Guidelines Panel-Depression in primary care: Clinical practice guideline no. 5 AHCPR pub No 93 – 0550,. Rockville MD 1993
-
12
Rush A J, Trivedi M H, Wisniewski S R. et al .
Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.
N Engl J Med.
2006;
354
1231-1242
-
13
Taylor D, Stewart S, Connolly A.
Antidepressant withdrawal symptoms-telephone calls to a national medication helpline.
J Affect Disord.
2006;
95
129-133
-
14
Dodd S, Horgan D, Malhi G. et al .
To combine or not to combine? A literature review of antidepressant combination therapy.
J Affect Disord.
2005;
89
1-11
-
15
Schmauß M, Messer T.
Kombination von Antidepressiva – eine sinnvolle Behandlungsstrategie bei therapieresistenten Depressionen?.
Fortschr Neurol Psychiat.
2009;
77
316-325
-
16 Schmauß M, Messer T. Polypharmazie in der Behandlung depressiver Störungen. Messer T, Schmauß M Polypharmazie in der Behandlung psychischer Erkrankungen Wien, New York; Springer 2009; im Druck 2. Aufl
-
17
Bauer M, Linden M.
Die Kombination verschiedener Antidepressiva in der Behandlung therapieresistenter Depressionen.
Nervenarzt.
1993;
64
343-347
-
18
Frye M A, Ketter T A, Leverich G S. et al .
The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study.
J Clin Psychiatry.
2000;
61
9-15
-
19
Murphy D L, Sunderland T, Cohen R M.
Monoamine oxidase-inhibiting antidepressants – a clinical update.
Psychiatr Clin North Am.
1984;
7
549-562
-
20
Schuckit M, Robins E, Feighner J.
Tricyclic antidepressants and monoamine oxidase inhibitors.
Arch Gen Psychiatry.
1971;
24
509-514
-
21 Schmauß M. Kombinationstherapie nicht-selektiver Monoamin-Rückaufnahme-Inhibitoren mit MAO-Hemmern. Riederer P, Laux G, Pöldinger W Neuro-Psychopharmaka. Bd 3: Antidepressiva Phasenprophylaktika und Stimmungsstabilisierer, Wien, New York; 2002 2. Aufl: 551-557
-
22
Steinberg R, Jost C, Weess H G. et al .
Combination of tricyclic antidepressants with moclobemide or tranylcypromine – outcome data in therapy resistant MD.
Neuropsychopharmacology (Suppl).
1994;
10
62
-
23
Koenig F, Wolfersdorf M.
Combination therapy using moclobemide with tricyclic and tetracyclic antidepressants to treat therapy-resistant depression.
Pharmacopsychiatry.
1997;
30
93-96
-
24
Neuvonen P, Pohjola-Sintonen S, Tacke U. et al .
Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses.
Lancet.
1993;
342
1419
-
25
Hawley C J, Quick S J, Ratnam S.
Safety and tolerability of combined treatment with moclobemide and SSRI: a systematic study of 50 patients.
Int Clin Psychopharmacol.
1996;
11
187-191
-
26
Dams R, Benijts T H, Lambert W E. et al .
A fatal case of serotonin syndrome after combined moclobemide-citalopram intoxication.
J Anal Toxicol.
2001;
25
147-151
-
27
Volz H P, Gleiter C H, Möller H J.
Monoaminoxidasehemmer in der Psychiatrie.
Nervenarzt.
1996;
67
339-347
-
28
Baron B M, Ogden A, Seigel B W. et al .
Rapid down regulation of β-adrenoreceptors by co-administration of desipramine and fluoxetine.
Eur J Pharmacol.
1988;
154
125-134
-
29
Nelson J C.
Augmentation strategies with serotonin-noradrenergic combinations.
J Clin Psychiatry.
1998;
59
65-68
-
30
Nelson J C, Mazure C M, Browers M BJ. et al .
A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression.
Arch Gen Psychiatry.
1991;
48
303-307
-
31
Dam J, Ryde L, Svejso J. et al .
Morning fluoxetine plus evening mianserin versus morning fluoxetine plus evening placebo in the acute treatment of major depression.
Pharmacopsychiatry.
1998;
31
48-54
-
32
Ferreri M, Lavergne F, Berlin I. et al .
Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone.
Acta Psychiatr Scand.
2001;
103
66-72
-
33
Maes M, Vandoolaeghe E, Desnyder R.
Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression.
J Affect Disord.
1996;
41
201-210
-
34
Harkin A, Kelly J P, McNamara M. et al .
Activity and onset of action of reboxetine and effect of combination with sertraline in an animal model of depression.
Eur J Pharmacol.
1999;
364
123-132
-
35
Carpenter L L, Yasmin S, Price H.
A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine.
Biol Psychiatry.
2002;
51
183-188
-
36 Debonnel G, Gobbi G, Turcotte J. et al .The alpha-2 antagonist mirtazapine combined with the SSRI paroxetine induces a greater antidepressant response: a double-blind controlled study. Presented at the 39th ACNP Meeting, Dec 10 – 14, San Juan, Puerto Rico, 2002.
-
37
Farah A.
Relief of SSRI-induced sexual dysfunction with mirtazapine treatment (letter).
J Clin Psychiatry.
1999;
60
260-261
-
38
McGrath P J, Stewart J W, Fava M. et al .
Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a Star*D report.
Am J Psychiatry.
2006;
163
1531-1541
-
39
Lam R W, Hossie H, Solomons K. et al .
Citalopram and bupropion SR: combining vs. switching in patients with treatment-resistant depression.
J Clin Psychiatry.
2004;
65
337-340
-
40
Papakostas G I, Worthington J J, Iosifescu D V. et al .
The combination of duloxetine and bupropion for treatment-resistant major depressive disorder.
Depress Anxiety.
2006;
3
178-181
-
41
DeBattista C, Solvason H B, Poirier J. et al .
A prospective trial of bupropion SR augmentation of partial and non-responsers to serotonergic antidepressants.
J Clin Psychopharmacol.
2003;
23
27-30
-
42
Zisook S, Rush A J, Haight B R. et al .
Use of bupropion in combination with serotonin reuptake inhibitors.
Biol Psychiatry.
2006;
59
203-210
-
43
Trivedi M H, Fava M, Wisniewski S R. et al .
Medication augmentation after the failure of SSRIs for depression.
N Engl J Med.
2006;
12
1243-1252
-
44
Lam R W, Wan D D, Cohen N L. et al .
Combining antidepressants for treatment-resistant depression. A review.
J Clin Psychiatry.
2002;
63
685-693
-
45
Bauer M, Whybrow P C.
Thyroid hormone, neural tissue and mood modulation.
World J Biol Psychiatry.
2001;
2
57-67
-
46
Baumgartner A.
Schilddrüsenhormone und depressive Erkrankungen. Teil I.
Nervenarzt.
1993;
64
1-10
-
47
Crossley N A, Bauer M.
Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analysis of randomized, placebo-controlled trials.
J Clin Psychiatry.
2007;
68
935-940
-
48
Bauer M, Forsthoff A, Baethge C. et al .
Lithium augmentation therapy in refractory depression – update 2002.
Eur Arch Psychiatry Clin Neurosci.
2003;
253
132-139
-
49
Zullino D, Baumann P.
Lithium augmentation in depressive patients not responding to selective serotonin reuptake inhibitors.
Pharmacopsychiatry.
2001;
34
119-127
-
50
Shelton R C, Papakostas G I.
Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder.
Acta Psychiatr Scand.
2008;
117
253-259
-
51
Shelton R C, Williamson D J, Corya S A. et al .
Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance.
J Clin Psychiatry.
2005;
66
1289-1297
-
52
Corya S A, Williamson D, Sanger T M. et al .
A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression.
Depression and Anxiety.
2006;
23
364-372
-
53
Papakostas G I, Shelton R C, Smith J. et al .
Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis.
J Clin Psychiatry.
2007;
68
826-831
-
54
Warneke L.
Psychostimulants in psychiatry.
Can J Psychiatry.
1990;
35
3-10
-
55
Robertson Jr P, Hellriegel E T.
Clinical pharmacokinetic profile of modafinil.
Clin Pharmacokinet.
2003;
42
123-137
-
56
Ninan P T, Hassman H A, Glass S J. et al .
Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatigue.
J Clin Psychiatry.
2004;
65
414-420
-
57
Landen M, Bjorling G, Agren H. et al .
A randomized, double-blind, placebocontrolled trial of buspirone in combination with an SSRI in patients with treatment refractory depression.
J Clin Psychiatry.
1998;
59
664-668
-
58 Sachs G, Collins M A, Altshuler L. et al .Divalproax sodium versus placebo for the treatment of bipolar depression. APA 2002 Syllabus & Proceedings Summary Washington DC 2002
-
59
Barbee J G, Jamhour N J.
Lamotrigine as an augmentation agent in treatment-resistant depression.
J Clin Psychiatry.
2002;
63 (Suppl 8)
737-741
-
60
Dietrich D E, Emrich H M.
The use of anticonvulsants to augment antidepressant medication.
J Clin Psychiatry.
1998;
59 (Suppl 5)
51-58
-
61
Cassano P, Lattanzi L, Fava M. et al .
Ropinirole in treatment-resistant depression: a 16-week pilot study.
Can J Psychiatry.
2005;
50
357-360
-
62
Dawson L A, Nguyen H Q.
The role of 5-HAT(1A) and 5-HAT(1B/ 1D) receptors on the modulation of acute fluoxetine-induced changes in extracellular 5-HAT: the mechanism of action of (+ /–) pindolol.
Neuropharmacology.
2000;
39
1044-1052
-
63
Olver J S, Cryan J F, Burrows G D. et al .
Pindolol augmentation of antidepressants: a review and rationale.
Aust N Z J Psychiatry.
2000;
34
71-79
-
64 Erfurth A, Möller H J. Vorgehen bei Antidepressiva-Nonrespondern. Möller HJ Therapie psychiatrischer Erkrankungen Stuttgart, New York; Thieme 2000 2. Aufl: 407-412
-
65 Abrams R. Electroconvulsive Therapy. Oxford, New York; Oxford University Press 2002
-
66
Pagnin D, Queiroz de V, Pini S. et al .
Efficacy of ECT in depression: a meta-analytic review.
J ECT.
2004;
20
13-20
-
67
American Psychiatric Association (APA) .
Practice guideline for the treatment of patients with major depressive disorder (revision).
Am J Psychiatry.
2000;
157
1-45
-
68 National Institute for Clinical Excellence .Depression: Management of depression in primary and secondary care. Clinical Guidelines 2004 23 http://www.nice.org.uk/CGO23 NICEguideline
-
69
UK ECT Review-Group .
Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis.
Lancet.
2003;
361
799-808
-
70
Bourgon L N, Kellner C H.
Relapse of depression after ECT: a review.
J ECT.
2000;
16
19-31
-
71
O’Reardon J P, Solvason H B, Janicak P G. et al .
Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial.
Biol Psychiatry.
2007;
62
1208-1216
-
72
Rush A J, George M S, Sackeim H A. et al .
Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study.
Biol Psychiatry.
2000;
47
276-286
-
73
Kuhn J, Huff W, Lee S H. et al .
Tiefenhirnstimulation bei psychiatrischen Erkrankungen.
Fortschr Neurol Psychiat.
2007;
75
447-457
-
74
Golden R N, Gaynes B N, Ekstrom R D. et al .
The efficacy of light therapy in the treatment of mood disorders. A review and meta-analysis of the evidence.
Am J Psychiatry.
2005;
62
656-662
-
75
Kennedy S H, Lam R W, Cohen N L. et al .
Clinical guidelines for the treatment of depressive disorders. IV: Medications and other biological treatments.
Can J Psychiatry.
2001;
46
38-58
-
76 Rush A J. Aktueller Stand und Perspektiven der Forschung. Bauer M, Berghöfer A, Adli M Akute und therapieresistente Depressionen Heidelberg; Springer 2005 2. Aufl: 3-19
-
77
Adli M, Rush A J, Möller H J.
Algorithms for optimizing the treatment of depression: making the right decision at the right time.
Pharmacopsychiatry.
2003;
36
222-229
-
78
Adli M, Bauer M, Rush A J.
Algorithms and collaborative-care systems for depression: are they effective and why? A systematic review.
Biol Psychiatry.
2006;
59
1029-1038
-
79
Trivedi M H, Rush A J, Crismon M L. et al .
Texas Medication Algorithm Project (TMAP): Clinical results for patients with major depressive disorder.
Arch Gen Psychiatry.
2004;
61
669-680
-
80 DGPPN .S3-Leitlinie zur Behandlung depressiver Störungen. Darmstadt; Steinkopff 2009; im Druck
-
81
Canadian Psychiatric Association .
Clinical guidelines for the treatment of depressive disorders.
Can J Psychiatry.
2001;
46 (Suppl 1)
13-90
-
82
Menke R, Gaebel W.
Leitlinienkonformität in Klinik und Praxis.
Psychopharmakotherapie.
2005;
12 (Suppl 13)
3-7
-
83 Bauer M, Whybrow P C, Angst J. et al .Biologische Behandlung unipolarer depressiver Störungen, Behandlungsleitlinien der World Federation of Societies of Biological Psychiatry (WFSBP). Stuttgart; Wissenschaftliche Verlagsgesellschaft 2004
Prof. Dr. med. M. Schmauß
Ärztlicher Direktor, Bezirkskrankenhaus Augsburg
Dr.-Mack-Straße 1
86156 Augsburg
Email: m.schmauss@bkh-augsburg.de
